Antilipolytic effect of propranolol in the dog

A. O. Grassi, M. N F de Lew, H. E. Cingolani

Research output: Contribution to journalArticle

Abstract

1 mg/kg body weight dose of propranolol, a blocking agent of the β-adrenergic receptors, was administered to anesthetized and unanesthetized dogs that were trained and tranquilized.-. Under these conditions the metabolic variations detected in plasma were the following: 1. 1) Decrease in the level of FFA 2. 2) Decrease in glycerol 3. 3) Increase in the level of glucose. The decrease of the glycerol and FFA concentrations seemed to indicate an antilipolytic effect of propranolol in the intact, sedated dog.-.

Original languageEnglish (US)
Pages (from-to)1239-1245
Number of pages7
JournalLife Sciences
Volume8
Issue number21 PART 1
StatePublished - Nov 1 1969
Externally publishedYes

Fingerprint

Propranolol
Glycerol
Dogs
Adrenergic Receptors
Body Weight
Plasmas
Glucose

ASJC Scopus subject areas

  • Pharmacology

Cite this

Grassi, A. O., de Lew, M. N. F., & Cingolani, H. E. (1969). Antilipolytic effect of propranolol in the dog. Life Sciences, 8(21 PART 1), 1239-1245.

Antilipolytic effect of propranolol in the dog. / Grassi, A. O.; de Lew, M. N F; Cingolani, H. E.

In: Life Sciences, Vol. 8, No. 21 PART 1, 01.11.1969, p. 1239-1245.

Research output: Contribution to journalArticle

Grassi, AO, de Lew, MNF & Cingolani, HE 1969, 'Antilipolytic effect of propranolol in the dog', Life Sciences, vol. 8, no. 21 PART 1, pp. 1239-1245.
Grassi AO, de Lew MNF, Cingolani HE. Antilipolytic effect of propranolol in the dog. Life Sciences. 1969 Nov 1;8(21 PART 1):1239-1245.
Grassi, A. O. ; de Lew, M. N F ; Cingolani, H. E. / Antilipolytic effect of propranolol in the dog. In: Life Sciences. 1969 ; Vol. 8, No. 21 PART 1. pp. 1239-1245.
@article{12a5e9149b584e5382e8211baff6d43b,
title = "Antilipolytic effect of propranolol in the dog",
abstract = "1 mg/kg body weight dose of propranolol, a blocking agent of the β-adrenergic receptors, was administered to anesthetized and unanesthetized dogs that were trained and tranquilized.-. Under these conditions the metabolic variations detected in plasma were the following: 1. 1) Decrease in the level of FFA 2. 2) Decrease in glycerol 3. 3) Increase in the level of glucose. The decrease of the glycerol and FFA concentrations seemed to indicate an antilipolytic effect of propranolol in the intact, sedated dog.-.",
author = "Grassi, {A. O.} and {de Lew}, {M. N F} and Cingolani, {H. E.}",
year = "1969",
month = "11",
day = "1",
language = "English (US)",
volume = "8",
pages = "1239--1245",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "21 PART 1",

}

TY - JOUR

T1 - Antilipolytic effect of propranolol in the dog

AU - Grassi, A. O.

AU - de Lew, M. N F

AU - Cingolani, H. E.

PY - 1969/11/1

Y1 - 1969/11/1

N2 - 1 mg/kg body weight dose of propranolol, a blocking agent of the β-adrenergic receptors, was administered to anesthetized and unanesthetized dogs that were trained and tranquilized.-. Under these conditions the metabolic variations detected in plasma were the following: 1. 1) Decrease in the level of FFA 2. 2) Decrease in glycerol 3. 3) Increase in the level of glucose. The decrease of the glycerol and FFA concentrations seemed to indicate an antilipolytic effect of propranolol in the intact, sedated dog.-.

AB - 1 mg/kg body weight dose of propranolol, a blocking agent of the β-adrenergic receptors, was administered to anesthetized and unanesthetized dogs that were trained and tranquilized.-. Under these conditions the metabolic variations detected in plasma were the following: 1. 1) Decrease in the level of FFA 2. 2) Decrease in glycerol 3. 3) Increase in the level of glucose. The decrease of the glycerol and FFA concentrations seemed to indicate an antilipolytic effect of propranolol in the intact, sedated dog.-.

UR - http://www.scopus.com/inward/record.url?scp=0014603884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014603884&partnerID=8YFLogxK

M3 - Article

C2 - 5358660

AN - SCOPUS:0014603884

VL - 8

SP - 1239

EP - 1245

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 21 PART 1

ER -